Search results
Results from the WOW.Com Content Network
Montelukast is in the leukotriene receptor antagonist family of medications. [6] It works by blocking the action of leukotriene D4 in the lungs resulting in decreased inflammation and relaxation of smooth muscle. [6] Montelukast was approved for medical use in the United States in 1998. [6] It is available as a generic medication. [8]
U.S. government researchers have found that a widely prescribed asthma drug originally sold by Merck & Co may be linked to serious mental health problems for some patients, according to a ...
The medical uses for Cysteinyl-leukotriene type 1 receptor antagonists are for chronic and prophylactic treatment of asthma. [3] [9] [10] Other indications have been approved by the FDA for montelukast and they are used for the prevention of exercise-induced bronchoconstriction (EIB), relief of symptoms of allergic rhinitis (AR) that is for relief of seasonal allergic rhinitis and perennial ...
It is not necessarily true that a physician and patient will have a conversation about a drug's boxed warning after it is issued. [4] For instance, an FDA-mandated boxed warning decreased rosiglitazone use by 70%, but that still meant 3.8 million people were given the drug.
Older patients are at a higher risk of experiencing CNS side effects. [ citation needed ] The link possible between anticholinergic medication use and cognitive decline/dementia has been noted in weaker observational studies. [ 21 ]
Mast cell activation syndrome (MCAS) is a term referring to one of two types of mast cell activation disorder (MCAD); the other type is idiopathic MCAD. [1] MCAS is an immunological condition in which mast cells, a type of white blood cell, inappropriately and excessively release chemical mediators, such as histamine, resulting in a range of chronic symptoms, sometimes including anaphylaxis or ...
Dementia-like symptoms have been found in some individuals who have been exposed to glucocorticoid medication, often dispensed in the form of asthma, arthritis, and anti-inflammatory steroid. [2] The term "steroid dementia" was coined by Varney et al. (1984) in reference to the effects of long-term glucocorticoid use in 1,500 patients. [3]
An antileukotriene, also known as leukotriene modifier and leukotriene receptor antagonist, is a medication which functions as a leukotriene-related enzyme inhibitor (arachidonate 5-lipoxygenase) or leukotriene receptor antagonist (cysteinyl leukotriene receptors) and consequently opposes the function of these inflammatory mediators; leukotrienes are produced by the immune system and serve to ...